

# **ASX** Release

## **Expired Options**

MELBOURNE, 3 February 2021: Anatara Lifesciences Ltd (ASX:ANR) advises that the following unquoted Options have expired and been cancelled:

### **Unquoted Securities – expired & cancelled:**

ASX Code	Security Description	Number
ANRAE	Options Expiring 14 December 2020 Exercisable at \$1.45	562,500
ANRAH	Options Expiring 14 December 2020 Exercisable at \$1.45	750,000
		1,312,500

#### **Unquoted Securities – on issue following the above cancelled Options:**

ASX Code	Security Description	Number
ANRAF	Options Expiring 23 September 2021 Exercisable at \$1.70	210,000
ANRAG	Options Expiring 17 November 2022 Exercisable at \$2.27	36,000
ANRAI	Options Expiring 17 February 2024 Exercisable at \$0.736	600,000
ANRAL	Options Expiring 3 December 2023 Exercisable at \$0.25	1,500,000
ANRAM	Options Expiring 3 December 2023 Exercisable at \$0.2276	617,704
		2,963,704

STEPHEN DENARO COMPANY SECRETARY

#### For more information please contact:

Investor and Media inquiries				
Steven Lydeamore CEO, Anatara Lifesciences Ltd. +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd. +61 (0) 437 211 200 smacleman@anatara.com			

#### **About Anatara Lifesciences Ltd**

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.